Next-Gen Lab Informatics Part 3: Procedure Execution

expand_more

29 views3 months ago

thumb_upLikes

thumb_downDislikes

library_addSave

flagReport

Labroots check_circle

1K subscribers

Presented By: Stephen Hayward Speaker Biography: Stephen Hayward has a PhD in Chemical Engineering, with a background in laboratory informatics, chemical modeling, and environmental analysis. Originally from Toronto, Canada, he currently leads product marketing efforts for informatics solutions at Dassault Systèmes BIOVIA in San Diego. Webinar: Next-Gen Lab Informatics Part 3: Procedure Execution Webinar Abstract: The "Next-Gen Lab Informatics" webinar series explores the dynamic realm of Quality Control (QC) and analytical testing, spotlighting Laboratory Execution Systems (LES), a crucial component for reshaping the execution of lab procedures. This webinar aims to bridge the gap between laboratory science and informatics by showcasing how cutting-edge technologies are influencing QC labs. Labroots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc

,5amToiO4s8I,UCP7xodi1WBjs2hNvEjow6ig, Knowledge, channel_UCP7xodi1WBjs2hNvEjow6ig, video_5amToiO4s8I

vid:241630

Comments0

unfold_more

00:55:48

Cannabis as Immunonotherapy for 21st Century Acquired Immune Deficiencies

more_vert

Labroots check_circle

40K views 6 years ago

,Presented At: Cannabis Sciences Virtual Event 2018 Presented By: Judy Mikovits, PhD - Founder/Consultant at M.A.R.C. INC and Director of Cancer Biology at EpiGenX Pharmaceuticals Speaker Bio: Dr. Judy A. Mikovits earned a BA in Chemistry with a specialization in biology from the University of Virginia in 1980 and a PhD in biochemistry and molecular biology from George Washington University in 1992. Upon graduation from UVA, she went directly to the National Cancer Institute in Frederick Maryland where she developed purification methods for Interferon alpha. It was this Interferon which was used in the first immune therapy treatment for hairy cell leukemia in 1986. In 1986-7, prior to enrolling in graduate school. she went to Upjohn Pharmaceuticals in Kalamazoo Michigan to develop production methods to insure biological materials manufactured using human blood products were free of contamination from HIV-1. Her PhD thesis defense entitled "Negative Regulation of HIV Expression in Monocytes" changed the paradigm for therapeutic treatment of HIV. For this work, she was awarded the graduate student of the year in 1991. In her thirty-five-year quest to understand and develop therapies for chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. In 2006, Dr. Mikovits became attracted to the plight of families with neuroimmune diseases including ME/CFS and Autism and was primarily responsible for demonstrating the relationship between environmentally acquired immune dysfunction, chronic inflammation and these diseases. Her pioneering work during a twenty year career at the National Cancer Institute includes the discovery of the modulation of DNA Methylation machinery by human retro viral infection and the development of the concept of inflammatory cytokines and chemokine signatures of infection and disease, which was first published in 1999, when Dr. Mikovits directed the Laboratory of Antiviral Drug Mechanisms in developing therapeutics and diagnostics for HIV/AIDS and AIDS associated malignancies. Webinar: Cannabis as Immunonotherapy for 21st Century Acquired Immune Deficiencies Webinar Abstract: It has only been in the last 20 years that we, the scientific/medical community, have appreciated the role of the endogenous Cannabinoid system (ECS) in maintaining a healthy immune system and brain. More recently, we recognized that the ECS is critical for stem cell development and homeostasis. The phytocannabinoid, THC is a modulator of Hematopoietic Stem Cells (HSC). It acts in part via stimulation of TGF beta production. The modulation of TGF beta, HSC and the NFkB by other natural product immunotherapy via some of the same pathways as THC suggest opportunities for synergy and decreasing psychoactive effects. Combinations of phytocannabinoiss can be used as stem cell and immune therapy in combination with other natural products and chemotherapy as curative treatment strategies for cancer, AIDS, Autoimmune disease and chronic inflammatory diseases. Moreover, Evidence is accumulating that THC is actually reduces opioid addiction by modulating endogenous opioids. Endogenous opioids are peptides derived from food which can also modulate immune cells including hematopoietc stem cells and be valuable therapeutics against HIV/AIDS and Cancer as our collaborator, Candace Pert demonstrated in the 1980s when she/we developed peptide T as an AIDS and cancer therapeutic (book Molecules of Emotion). Endocannabinoids, phyto-cannabinoids, and opioids modulate the immune system, hematopoietic and mesenchymal stem cells, it may also modulate the opioid pathways to reduce addiction. Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/cannabis-sciences-2018) 2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/cannabis-sciences-2018) 3. Click Here to get your PACE (Expiration date – March 29, 2020 12:00 PM)– http://www.labroots.com/credit/pace-credits/2816/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc